Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Non-Current Deffered Revenue (2021 - 2023)

Spyre Therapeutics (SYRE) has disclosed Non-Current Deffered Revenue for 3 consecutive years, with $2.3 million as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Non-Current Deffered Revenue fell 1.31% year-over-year to $2.3 million, compared with a TTM value of $2.3 million through Jun 2023, down 1.31%, and an annual FY2022 reading of $2.2 million, up 79.05% over the prior year.
  • Non-Current Deffered Revenue was $2.3 million for Q2 2023 at Spyre Therapeutics, roughly flat from $2.3 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $2.4 million in Q2 2022 and bottomed at $740000.0 in Q1 2022.
  • Average Non-Current Deffered Revenue over 3 years is $2.0 million, with a median of $2.2 million recorded in 2021.
  • The sharpest move saw Non-Current Deffered Revenue tumbled 67.46% in 2022, then surged 216.35% in 2023.
  • Year by year, Non-Current Deffered Revenue stood at $1.2 million in 2021, then skyrocketed by 79.05% to $2.2 million in 2022, then rose by 7.43% to $2.3 million in 2023.
  • Business Quant data shows Non-Current Deffered Revenue for SYRE at $2.3 million in Q2 2023, $2.3 million in Q1 2023, and $2.2 million in Q4 2022.